Low Psychosine in Krabbe Disease with Onset in Late Infancy: A Case Report
- PMID: 34071213
- PMCID: PMC8162352
- DOI: 10.3390/ijns7020028
Low Psychosine in Krabbe Disease with Onset in Late Infancy: A Case Report
Abstract
Krabbe disease (KD) is a rare inherited neurodegenerative disorder caused by a deficiency in galactocerebrosidase enzyme activity, which can present in early infancy, requiring an urgent referral for hematopoietic stem cell transplantation, or later in life. Newborn screening (NBS) for KD requires identification and risk-stratification of patients based on laboratory values to predict disease onset in early infancy or later in life. The biomarker psychosine plays a key role in NBS algorithms to ascertain probability of early-onset disease. This report describes a patient who was screened positive for KD in New York State, had a likely pathogenic genotype, and showed markedly reduced enzyme activity but surprisingly low psychosine levels. The patient ultimately developed KD in late infancy, an outcome not clearly predicted by existing NBS algorithms. It remains critical that psychosine levels be evaluated alongside genotype, enzyme activity levels, and the patient's evolving clinical presentation, ideally in consultation with experts in KD, in order to guide diagnosis and plans for monitoring.
Keywords: Krabbe disease; newborn screening; psychosine.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
The critical role of psychosine in screening, diagnosis, and monitoring of Krabbe disease.Genet Med. 2020 Jun;22(6):1108-1118. doi: 10.1038/s41436-020-0764-y. Epub 2020 Feb 24. Genet Med. 2020. PMID: 32089546
-
Psychosine, a marker of Krabbe phenotype and treatment effect.Mol Genet Metab. 2017 Jul;121(3):271-278. doi: 10.1016/j.ymgme.2017.05.015. Epub 2017 May 22. Mol Genet Metab. 2017. PMID: 28579020 Free PMC article.
-
Development of a newborn screening tool based on bivariate normal limits: using psychosine and galactocerebrosidase determination on dried blood spots to predict Krabbe disease.Genet Med. 2019 Jul;21(7):1644-1651. doi: 10.1038/s41436-018-0371-3. Epub 2018 Dec 14. Genet Med. 2019. PMID: 30546085
-
Consensus guidelines for newborn screening, diagnosis and treatment of infantile Krabbe disease.Orphanet J Rare Dis. 2018 Feb 1;13(1):30. doi: 10.1186/s13023-018-0766-x. Orphanet J Rare Dis. 2018. PMID: 29391017 Free PMC article. Review.
-
A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease.Int J Neonatal Screen. 2022 Nov 15;8(4):61. doi: 10.3390/ijns8040061. Int J Neonatal Screen. 2022. PMID: 36412587 Free PMC article. Review.
Cited by
-
Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements.Int J Neonatal Screen. 2024 Jan 28;10(1):10. doi: 10.3390/ijns10010010. Int J Neonatal Screen. 2024. PMID: 38390974 Free PMC article.
-
The Editor's Choice for Issue 2, Volume 7.Int J Neonatal Screen. 2021 Sep 18;7(3):61. doi: 10.3390/ijns7030061. Int J Neonatal Screen. 2021. PMID: 34564081 Free PMC article.
-
Globoid Cell Leukodystrophy (Krabbe Disease): An Update.Immunotargets Ther. 2023 Oct 31;12:105-111. doi: 10.2147/ITT.S424622. eCollection 2023. Immunotargets Ther. 2023. PMID: 37928748 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous